Home/Pipeline/AMNIOBURN®

AMNIOBURN®

Partial-Thickness Burns

Clinical EvaluationCommercial

Key Facts

Indication
Partial-Thickness Burns
Phase
Clinical Evaluation
Status
Commercial
Company

About MiMedx Group

MiMedx Group is a vertically integrated biopharmaceutical company focused on developing, processing, and commercializing regenerative placental tissue allografts for advanced wound care and surgical applications. Its core competitive advantage is the proprietary PURION® processing platform, which preserves the biological integrity of the tissue to create a diverse portfolio of products. The company has achieved significant commercial traction with over three million allografts distributed and payer coverage for over 300 million lives, positioning it as a leader in the placental biologics space. MiMedx's strategy centers on expanding its clinical evidence, penetrating existing markets, and exploring new surgical indications to drive growth.

View full company profile

Other Partial-Thickness Burns Drugs

DrugCompanyPhase
CohealyxAVITA MedicalApproved
PermeaDermAVITA MedicalApproved